Skip to main content

Table 2 Treatment and response

From: Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy

 

All patients

PSA relapse

PSA persistence

ADT

 ADT with stop before last follow up / duration (months)

43 / 5 (2–25)

22 / 4.5 (2–23)

21 / 5.5 (2–25)

 Ongoing ADT at last follow up

30

3

27

 No ADT

56

37

19

Median PSA before RT

0.62 (< 0.03–40.13)

0.44 (0.15–10.6)

0.90 (< 0.03–40.13)

RT

 Former Prostate

66 Gy (63–66)

 Lymphatic pathways

50.4 Gy (45–52.3)

 Local recurrence

70 Gy (66–70.6)

 PET pos. LN

61.6 Gy (53.2–66)

RT technique

 VMAT/IMRT & IGRT

All pts.

Median Follow-up (months)

20 (3–42)

First PSA after RT

n = 121a

n = 58b

n = 63b

 Median PSA

0.07 (< 0.03–13.71)

0.07 (< 0.03–0.56)

0.07 (< 0.03–13.71)

 PSA ≤ 0.1 ng/ml

89 (74%)

47 (81%)

42 (67%)

 PSA ≤ 0.2 ng/ml

98 (81%)

50 (86%)

48 (76%)

PSA at last median follow-up

n = 121a

n = 58b

n = 63b

 Median PSA

0.07 (< 0.03–35)

0.07 (< 0.03–1)

0.07 (0.01–35)

 PSA ≤ 0.1 ng/ml

82%

87%

77%

 PSA ≤ 0.2 ng/ml

84%

91%

78%

PSA at last median follow-up with ADT

n = 30

n = 2

n = 28

 Median PSA

0.06 (< 0.03–13.71)

< 0.03

0.07 (< 0.03–13.71)

 PSA ≤ 0.1 ng/ml

79%

100%

79%

 PSA ≤ 0.2 ng/ml

83%

100%

82%

PSA at last median follow-up without ADT

n = 91

n = 56

n = 35

 Median PSA

0.07 (< 0.03–35)

0.07 (< 0.03–1)

0.08 (< 0.03–35)

 PSA ≤ 0.1 ng/ml

83%

87%

78%

 PSA ≤ 0.2 ng/ml

85%

91%

78%

PSA at last median follow-up in PET pos. pts

n = 72

n = 29

n = 43b

 Median PSA

0.06 (< 0.03–35)

0.03 (< 0.03–0.46)

0.07 (< 0.03–35)

 PSA ≤ 0.1 ng/ml

84%

94%

77%

 PSA ≤ 0.2 ng/ml

86%

94%

79%

PSA at last median follow-up in PET pos. pts without ADT

n = 45

n = 27

n = 18

 Median PSA

0.05 (< 0.03–35)

0.04 (< 0.03–0.46)

0.13 (< 0.03–35)

 PSA ≤ 0.1 ng/ml

89%

94%

82%

 PSA ≤ 0.2 ng/ml

89%

94%

82%

PSA at last follow-up in PET neg. pts

n = 49

n = 29

n = 20

 Median PSA

0.07 (< 0.03–3.23)

0.07 (< 0.03–1)

0.08 (< 0.03–3.23)

 PSA ≤ 0.1 ng/ml

78%

79%

77%

 PSA ≤ 0.2 ng/ml

83%

87%

77%

Clinical Progress

 Distant Metastases

  

14

  1. PSA prostate specific antigen, ADT androgen deprivation therapy, LN lymph nodes, RT radiation therapy, VMAT volumetric modulated arc therapy, IMRT intensity modulated radiotherapy, IGRT image guided radiotherapy
  2. aPSA follow-up missing in eight patients
  3. bPSA follow-up missing in four patients